Rejuran

Rejuran – Polynucleotide Injectable Gel

Rejuran is a sterile injectable gel containing sodium polynucleotide. It is administered by a qualified health practitioner using a thin gauge needle into the mid to deep dermis. The procedure is performed under sterile conditions (TGA, 2026).

Potential side effects and risks may include:

• Redness, swelling, or bruising at the injection site

• Tenderness or discomfort during or after the procedure

• Itching or irritation

• Infection or allergic reaction

Recovery and individual experience

• Some mild swelling or redness may persist for a few days following the procedure.

• Most people are able to return to normal daily activities immediately, although minor discomfort at the injection site may last for several days.

• Individual responses vary. Recovery time and experience may differ between people.

• Outcomes experienced by one person do not necessarily reflect the outcomes that other people may experience.

Patients will have a thorough consult prior to any treatment to determine suitability.'

Leigh Pritchard 

Registered Nurse - NMW0002347730

Reference

Therapeutic Goods Administration. (2026, March 17). Public summary for ARTG entry: 412630 K Bridge Medical Pty Ltd – REJURAN – Dermal tissue reconstructive material, animal‑derived. Australian Government. Retrieved March 24, 2026, from https://www.ebs.tga.gov.au/servlet/xmlmillr6?dbid=ebs/PublicHTML/pdfStore.nsf&docid=412630&agid=%28PrintDetailsPublic%29&actionid=1